Avo vs SimpleSense

Nanowear's 303-subject prospective multicentre study of its cuffless blood pressure monitor (J Cardiovasc Transl Res 2025) came from vendor-affiliated authors, ran four weeks and was internal validation only, and the authors call for external validation. A 2022 Sci Rep paper on its multiparametric cloth-based SimpleSense estimating blood pressure carries the same Nanowear affiliation. The garment and its cloud analytics hold four FDA 510(k) clearances, the newest SimpleSense-BP in December 2023. The company is in Brooklyn and was founded in 2014, and listed funding is $1.52M over two rounds per Tracxn. A heart failure clinic or cardiology practice is the buyer, with no public price.

A medical director rolling out documentation and decision support looks to Avo, whose homepage figures are vendor claims with no study link: a 35% cut in note time per patient and $11.6M in annual savings at an ambulatory organization. One is remote cardiometabolic monitoring bought by a clinic, the other chart tooling bought by a health system.